A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
The purpose of this study is to evaluate the safety and antiviral activity of
 ABT-450/ritonavir/ABT- 267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267
 also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin
 (RBV) in patients with chronic hepatitis C virus genotype 1a (HCV GT1a) infection without
 cirrhosis.
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and
 antiviral activity of the combination of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and
 ABT-333 with and without ribavirin (RBV) in treatment-naive, noncirrhotic participants with
 chronic hepatitis C virus genotype 1a (HCV GT1a) infection.
Inclusion Criteria:

 -  Females must be practicing specific forms of birth control on study treatment, or be
 post-menopausal for more than 2 years or surgically sterile

 -  Chronic hepatitis C, genotype 1a-infection (HCV RNA level greater than or equal to
 10,000 IU/mL at screening)

 -  Subject has never received antiviral treatment for hepatitis C infection

 -  No evidence of liver cirrhosis

 Exclusion Criteria:

 -  Significant liver disease with any cause other than HCV as the primary cause

 -  Positive hepatitis B surface antigen or anti-human immunodeficiency virus antibody

 -  Positive screen for drugs or alcohol

 -  Significant sensitivity to any drug

 -  Use of contraindicated medications within 2 weeks of dosing

 -  Abnormal laboratory tests